Jennifer Eriksson

New insights into the burden and costs of multiple sclerosis in Europe

Gisela Kobelt, Alan J. Thompson, Jenny Berg et al. · Multiple Sclerosis Journal · 2017 · 729 citations · Full text

Pharmacy, Pharmacoeconomics, Cost-utility Analysis +16

Health-Related Quality of Life and Utility in Patients with Advanced Non–Small-Cell Lung Cancer: A Prospective Cross-Sectional Patient Survey in a Real-World Setting

C. Chouaïd, Jason Agulnik, Erdem Göker et al. · Journal of Thoracic Oncology · 2013 · 144 citations · Full text

Pharmacy, Oncology, Health Assessment +16

Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Marianne Pavel, Simron Singh, Jonathan Strosberg et al. · The Lancet Oncology · 2017 · 84 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

The burden of multiple sclerosis 2015: Methods of data collection, assessment and analysis of costs, quality of life and symptoms

Gisela Kobelt, Jennifer Eriksson, Glenn Phillips et al. · Multiple Sclerosis Journal · 2017 · 77 citations · Full text

Pharmacy, Health Sciences, Neurology +17

Quality of Life and Utility in Patients with Metastatic Soft Tissue and Bone Sarcoma: The Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE) Study

Peter Reichardt, Michael Leahy, Xavier García del Muro et al. · Sarcoma · 2012 · 63 citations · Full text

Medicine, Oncology, Chemotherapy +16